A Clinically Applicable Nomogram for Predicting the Risk of Invasive Mechanical Ventilation in Pneumocystis jirovecii Pneumonia

Abstract

ObjectivePneumocystis jirovecii pneumonia (PCP) is a life-threatening disease associated with a high mortality rate among immunocompromised patient populations. Invasive mechanical ventilation (IMV) is a crucial component of treatment for PCP patients with progressive hypoxemia. This study explored the risk factors for IMV and established a model for early predicting the risk of IMV among patients with PCP.MethodsA multicenter, observational cohort study was conducted in 10 hospitals in China. Patients diagnosed with PCP were included, and their baseline clinical characteristics were collected. A Boruta analysis was performed to identify potentially important clinical features associated with the use of IMV during hospitalization. Selected variables were further analyzed using univariate and multivariable logistic regression. A logistic regression model was established based on independent risk factors for IMV and visualized using a nomogram.ResultsIn total, 103 patients comprised the training cohort for model development, and 45 comprised the validation cohort to confirm the model’s performance. No significant differences were observed in baseline clinical characteristics between the training and validation cohorts. Boruta analysis identified eight clinical features associated with IMV, three of which were further confirmed to be independent risk factors for IMV, including age (odds ratio [OR] 2.615 [95% confidence interval (CI) 1.110–6.159]; p = 0.028), oxygenation index (OR 0.217 [95% CI 0.078–0.604]; p = 0.003), and serum lactate dehydrogenase level (OR 1.864 [95% CI 1.040–3.341]; p = 0.037). Incorporating these three variables, the nomogram achieved good concordance indices of 0.829 (95% CI 0.752–0.906) and 0.818 (95% CI 0.686–0.950) in predicting IMV in the training and validation cohorts, respectively, and had well-fitted calibration curves.ConclusionsThe nomogram demonstrated accurate prediction of IMV in patients with PCP. Clinical application of this model enables early identification of patients with PCP who require IMV, which, in turn, may lead to rational therapeutic choices and improved clinical outcomes.

A nomogram for predicting the risk of mortality in patients with acute pancreatitis and Gram-negative bacilli infection

“…Furthermore, a receiver operating characteristic curve (ROC) was conducted to measure the predictive accuracy of the developed model, and the area under the receiver operating characteristic curve (AUC) was calculated. Finally, this model was assessed using a bootstrap-based calibration process ( Wan et al., 2022 ) to evaluate the relationship between the actual and predicted probabilities of mortality. The statistical analyses mentioned above were performed using the RMS Version 6.2-0 and pROC Version 1.18.0 R package.…”

Metagenomic next-generation sequencing for identifying pathogens in patients with rheumatic diseases and diffuse pulmonary lesions: A retrospective diagnostic study

“…For patients with rheumatic disease, lung involvement is recognized as a major cause of morbidity and mortality ( Luppi et al., 2022 ). Besides, internal immune dysregulation and secondary immunosuppression caused by antirheumatic therapy make these patients vulnerable to pulmonary infections, including opportunistic infections, which can also present diffuse pulmonary lesions on chest radiography ( Di Franco et al., 2017 ; Wan et al., 2022 ). Due to the broad range of diagnostic and therapeutic aspects with an increased risk of mortality, rheumatic diseases complicated by diffuse pulmonary lesions are an important and challenging field in the clinical routine of both pulmonologists and rheumatologists.…”

The prognostic value of the combined neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-platelet ratio (NPR) in sepsis

“…For example, sepsis patients with an elevated NLR_NPR score may require more aggressive interventions, closer monitoring, and timely escalation of care. Additionally, these biomarkers may be used in the future to identify patients who may benefit from novel therapeutic strategies or targeted interventions aimed at modulating the immune response and improving outcomes in sepsis 42 .…”